Portrait of Hoang Minh Hieu Nguyen
Photo: Supplied photo via Forbes Asia · Publisher-directed editorial display; source copyright retained

FigureAsia 35 Under 35 · Healthcare

Hoang Minh Hieu Nguyen

Age 25 · Neurodegeneration research and telemedicine access · Stanford, United States

Vietnamese medical trainee who contributed to 2025 neurodegeneration research and helped establish a telemedicine pathway serving a rural Kenyan hospital.

Approximate age at 31 December 2025
25
Field
Healthcare
Country or region
Stanford, United States
FigureAsia U35 Assessment
80.0 / 100

Career and documented record

Hoang Minh Hieu Nguyen has built an early career across two very different forms of healthcare contribution. In 2025, he coauthored a PNAS study on neurodegeneration, adding to a laboratory record in the biology of neural disease. At the same time, his global-health work helped establish a telemedicine pathway for a hospital in Longisa, Kenya, including access to specialist input around dialysis.

The combination is important because it refuses a false choice between frontier research and delivery. Nguyen's medical training gives him a clinical frame for both, while his role on an international telehealth advisory body places him inside the operational questions of connectivity, local capacity and referral continuity.

The public record does not provide a patient denominator, comparative outcomes or evidence that Nguyen alone created the Longisa programme. He is a young contributor in collaborative science and service, not the sole owner of either result. FigureAsia includes him because the work is completed, internationally relevant and unusually substantive for a 25-year-old physician in training — with its scale described no more strongly than the evidence allows.

Why Hoang Minh Hieu Nguyen is on the list

FigureAsia selected Nguyen because his 2025 record joins rigorous biomedical inquiry to a concrete access pathway. His Vietnamese background and cross-border work embody the edition's view of the Asian diaspora as a source of reciprocal, not extractive, global engagement. The score is moderated by limited public outcome data and shared team attribution; the distinction lies in breadth, responsibility and trajectory rather than seniority.

The 2025–26 record

Principal milestone

Born in 2000

Evidence record

Coauthor of a 2025 PNAS neurodegeneration study

Scale or implementation

Telemedicine pathway established for a rural Kenyan hospital, including dialysis access

The work in its field

Within neurodegeneration research and telemedicine access, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.

Assessment breakdown

80.0out of 100

01

Substantive 2025–2026 contribution

16 / 20

The score reflects completed 2025–26 work in neurodegeneration research and telemedicine access, assessed at the documented maturity of collaborative research and implemented telemedicine pathway.

02

Verified impact

10.5 / 15

Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.

03

Originality and distinction

8 / 10

The work creates or materially advances a distinctive capability within neurodegeneration research and telemedicine access rather than relying on title or institutional association.

04

Field and industry influence

7 / 10

The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.

05

Individual agency

8 / 10

Named authorship and the documented role of Medical Student and Global-Health Researcher establish individual responsibility while preserving credit for collaborators.

06

Durability and trajectory

4.5 / 5

The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.

07

Asian significance and global relevance

5 / 5

The Asian connection is material to the person's identity, operating base or populations served: Born in 2000 and raised in Di Linh, Vietnam; now training in medicine in the United States.

08

Clinical and scientific validity

5.6 / 7

Clinical and scientific validity is calibrated to collaborative research and implemented telemedicine pathway, with the profile retaining the evidence boundary attached to the result.

09

Safety, quality and responsible governance

5.6 / 7

Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.

10

Translation and care-pathway fit

4.8 / 6

The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.

11

Access, equity and resource stewardship

5 / 5

Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.

Evidence and attribution

Material claims on this page are supported by the edition’s evidence record. FigureAsia tests age, identity, role, result and individual attribution before publication. Public profiles present the reported record; supporting documentation is retained for accuracy review and corrections.

Achievement records
3
Assessment window
2025–26
Editorial status
Included in the 2026 FigureAsia 35 Under 35 edition

Rights and credit

The portrait is published under the rights basis recorded for this edition. Third-party ownership and reuse restrictions remain in force.

Publication status
Published under a documented rights basis
Credit
Supplied photo via Forbes Asia
Licence
Publisher-directed editorial display; source copyright retained
Portrait source and credit